The Living scar - cardiac fibroblasts and the injured heart

Trends in Molecular Medicine

Volumn 22, Issue 2, 2016, Pages 99-114

  Rog Zielinska, Eva A ^a,b   Norris, Russell A ^c   Kohl, Peter ^a,b   Markwald, Roger ^c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cardiac; Fibrosis; Non myocyte

Indexed keywords

CAVEOLIN; MICRORNA; TRANSCRIPTION FACTOR RUNX2; CCL2 PROTEIN, HUMAN; CXCL10 PROTEIN, HUMAN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA;

BIOPHYSICS; CELL FUNCTION; CELL INTERACTION; CELL STRUCTURE; HEART FIBROBLAST; HEART INJURY; HEART MUSCLE CELL; HUMAN; PROTEIN TARGETING; REVIEW; SCAR FORMATION; AUTOCRINE EFFECT; CARDIAC MUSCLE CELL; CELL MOTION; FIBROBLAST; GAP JUNCTION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PARACRINE SIGNALING; PATHOLOGY; SCAR; SIGNAL TRANSDUCTION; ULTRASTRUCTURE;

AUTOCRINE COMMUNICATION; CELL MOVEMENT; CHEMOKINE CCL2; CHEMOKINE CXCL10; CICATRIX; FIBROBLASTS; GAP JUNCTIONS; GENE EXPRESSION REGULATION; HEART INJURIES; HUMANS; MICRORNAS; MYOCYTES, CARDIAC; PARACRINE COMMUNICATION; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84955558498     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2015.12.006     Document Type: Review

References (171)

1. Adler C.P., et al. DNA content and cell number in heart and liver of children. Comparable biochemical, cytophotometric and histological investigations. Pathol. Res. Pract. 1981, 172:25-41.
2. Camelliti P., et al. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc. Res. 2005, 65:40-51.
3. Chen W., Frangogiannis N.G. Fibroblasts in post-infarction inflammation and cardiac repair. Biochim. Biophys. Acta 2013, 1833:945-953.
4. Ertl G., Frantz S. Healing after myocardial infarction. Cardiovasc. Res. 2005, 66:22-32.
5. Goldsmith E.C., et al. Organization of fibroblasts in the heart. Dev. Dyn. 2004, 230:787-794.
6. Souders C.A., et al. Cardiac fibroblast: the renaissance cell. Circ. Res. 2009, 105:1164-1176.
7. Moore-Morris T., et al. Targeting cardiac fibroblasts: the pressure is on. Cell Cycle 2014, 13:2647-2648.
8. Sangaralingham S.J., et al. The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic peptide. Hypertension 2011, 57:201-207.
9. Platonov P.G., et al. Structural abnormalities in atrial walls are associated with presence and persistency of atrial fibrillation but not with age. J. Am. College Cardiol. 2011, 58:2225-2232.
10. Zeppenfeld K., et al. Catheter ablation of ventricular tachycardia after repair of congenital heart disease: electroanatomic identification of the critical right ventricular isthmus. Circulation 2007, 116:2241-2252.
11. Desmouliere A., et al. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am. J. Pathol. 1995, 146:56-66.
12. Czubryt M.P. Common threads in cardiac fibrosis, infarct scar formation, and wound healing. Fibrogenesis Tissue Repair 2012, 5:19.
13. Camelliti P., et al. Spatially and temporally distinct expression of fibroblast connexins after sheep ventricular infarction. Cardiovasc. Res. 2004, 62:415-425.
14. Virag J.I., Murry C.E. Myofibroblast and endothelial cell proliferation during murine myocardial infarct repair. Am. J. Pathol. 2003, 163:2433-2440.
15. Vanhoutte D., et al. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc. Res. 2006, 69:604-613.
16. Sun Y., et al. Infarct scar as living tissue. Basic Res. Cardiol. 2002, 97:343-347.
17. Sun Y., Weber K.T. Infarct scar: a dynamic tissue. Cardiovasc. Res. 2000, 46:250-256.
18. Pouliopoulos J., et al. Intramyocardial adiposity after myocardial infarction: new implications of a substrate for ventricular tachycardia. Circulation 2013, 128:2296-2308.
19. Ichikawa Y., et al. Adipose tissue detected by multislice computed tomography in patients after myocardial infarction. JACC: Cardiovasc. Imaging 2009, 2:548-555.
20. Fomovsky G.M., Holmes J.W. Evolution of scar structure, mechanics, and ventricular function after myocardial infarction in the rat. Am. J. Physiol. Heart Circ. Physiol. 2010, 298:H221-H228.
21. Vracko R., Thorning D. Contractile cells in rat myocardial scar tissue. Lab. Invest. J. Tech. Methods Pathol. 1991, 65:214-227.
22. Willems I.E., et al. The alpha-smooth muscle actin-positive cells in healing human myocardial scars. Am. J. Pathol. 1994, 145:868-875.
23. Gabbiani G., et al. Granulation tissue as a contractile organ. A study of structure and function. J. Exp. Med. 1972, 135:719-734.
24. Braitsch C.M., et al. Differential expression of embryonic epicardial progenitor markers and localization of cardiac fibrosis in adult ischemic injury and hypertensive heart disease. J. Mol. Cell. Cardiol. 2013, 65:108-119.
25. Turner N., Porter K. Function and fate of myofibroblasts after myocardial infarction. Fibrogenesis Tissue Repair 2013, 6:5.
26. Kohl P., Gourdie R.G. Fibroblast-myocyte electrotonic coupling: does it occur in native cardiac tissue?. J. Mol. Cell. Cardiol. 2014, 70:37-46.
27. Janse M.J., Wit A.L. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol. Rev. 1989, 69:1049-1169.
28. Nguyen T.P., et al. Cardiac fibrosis and arrhythmogenesis: the road to repair is paved with perils. J. Mol. Cell. Cardiol. 2014, 70:83-91.
29. de Bakker J.M., et al. Slow conduction in the infarcted human heart. 'Zigzag' course of activation. Circulation 1993, 88:915-926.
30. Soejima K., et al. Electrically unexcitable scar mapping based on pacing threshold for identification of the reentry circuit isthmus: feasibility for guiding ventricular tachycardia ablation. Circulation 2002, 106:1678-1683.
31. Biernacka A., Frangogiannis N.G. Aging and cardiac fibrosis. Aging Dis. 2011, 2:158-173.
32. Pratola C., et al. Radiofrequency ablation of atrial fibrillation: is the persistence of all intraprocedural targets necessary for long-term maintenance of sinus rhythm?. Circulation 2008, 117:136-143.
33. Hager A., et al. Congenital and surgically acquired Wolff-Parkinson-White syndrome in patients with tricuspid atresia. J. Thoracic Cardiovasc. Surg. 2005, 130:48-53.
34. Lefroy D.C., et al. Recipient-to-donor atrioatrial conduction after orthotopic heart transplantation: surface electrocardiographic features and estimated prevalence. Am. J. Cardiol. 1998, 82:444-450.
35. Kohl P., et al. Stretch-induced changes in heart rate and rhythm: clinical observations, experiments and mathematical models. Progress Biophys. Mol. Biol. 1999, 71:91-138.
36. De Maziere A.M., et al. Spatial and functional relationship between myocytes and fibroblasts in the rabbit sinoatrial node. J. Mol. Cell. Cardiol. 1992, 24:567-578.
37. Langevin H.M., et al. Fibroblasts form a body-wide cellular network. Histochem. Cell Biol. 2004, 122:7-15.
38. Fries K.M., et al. Evidence of fibroblast heterogeneity and the role of fibroblast subpopulations in fibrosis. Clin. Immunol. Immunopathol. 1994, 72:283-292.
39. Lekic P.C., et al. Is fibroblast heterogeneity relevant to the health, diseases, and treatments of periodontal tissues?. Crit. Rev. Oral Biol. Med. 1997, 8:253-268.
40. Burstein B., et al. Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences. Circulation 2008, 117:1630-1641.
41. Zeisberg E.M., Kalluri R. Origins of cardiac fibroblasts. Circ. Res. 2010, 107:1304-1312.
42. Moore-Morris T., et al. Cardiac fibroblasts: from development to heart failure. J. Mol. Med. 2015, 93:823-830.
43. Tomasek J.J., et al. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat. Rev. Mol. Cell Biol. 2002, 3:349-363.
44. Daskalopoulos E.P., et al. Myofibroblasts in the infarct area: concepts and challenges. Microsc. Microanalysis 2012, 18:35-49.
45. Weber K.T., et al. Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat. Rev. Cardiol. 2013, 10:15-26.
46. Hinz B. Formation and function of the myofibroblast during tissue repair. J. Invest. Dermatol. 2007, 127:526-537.
47. Hinz B., Gabbiani G. Mechanisms of force generation and transmission by myofibroblasts. Curr. Opin. Biotechnol. 2003, 14:538-546.
48. Desmoulière A., et al. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J. Cell Biol. 1993, 122:103-111.
49. Moore-Morris T., et al. Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis. J. Clin. Invest. 2014, 124:2921-2934.
50. Vasquez C., et al. The cardiac fibroblast: functional and electrophysiological considerations in healthy and diseased hearts. J. Cardiovasc. Pharmacol. 2011, 57:380-388.
51. Hinz B., et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am. J. Pathol. 2012, 180:1340-1355.
52. Negmadjanov U., et al. TGF-β1-mediated differentiation of fibroblasts is associated with increased mitochondrial content and cellular respiration. PLoS ONE 2015, 10:e0123046.
53. Yano T., et al. Intracardiac fibroblasts, but not bone marrow derived cells, are the origin of myofibroblasts in myocardial infarct repair. Cardiovasc. Pathol. 2005, 14:241-246.
54. + perivascular cells identify a major source of profibrotic cells during acute tissue injury. Nat. Med. 2012, 18:1262-1270.
55. Visconti R.P., Markwald R.R. Recruitment of new cells into the postnatal heart: potential modification of phenotype by periostin. Ann. N. Y. Acad. Sci. 2006, 1080:19-33.
56. Zhu F., et al. Senescent cardiac fibroblast is critical for cardiac fibrosis after myocardial infarction. PLoS ONE 2013, 8:e74535.
57. Ruiz-Villalba A., et al. Interacting resident epicardium-derived fibroblasts and recruited bone marrow cells form myocardial infarction scar. J. Am. College Cardiol. 2015, 65:2057-2066.
58. Krenning G., et al. The origin of fibroblasts and mechanism of cardiac fibrosis. J. Cell. Physiol. 2010, 225:631-637.
59. Zhou B., et al. Adult mouse epicardium modulates myocardial injury by secreting paracrine factors. J. Clin. Invest. 2011, 121:1894-1904.
60. Gittenberger-de Groot A.C., et al. The arterial and cardiac epicardium in development, disease and repair. Differentiation 2012, 84:41-53.
61. Mikawa T., Gourdie R.G. Pericardial mesoderm generates a population of coronary smooth muscle cells migrating into the heart along with ingrowth of the epicardial organ. Dev. Biol. 1996, 174:221-232.
62. Russell J.L., et al. A dynamic notch injury response activates epicardium and contributes to fibrosis repair. Circ. Res. 2011, 108:51-59.
63. Duan J., et al. Wnt1/β-catenin injury response activates the epicardium and cardiac fibroblasts to promote cardiac repair. EMBO J. 2012, 31:429-442.
64. Zeisberg E.M., et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med. 2007, 13:952-961.
65. Ali S.R., et al. Developmental heterogeneity of cardiac fibroblasts does not predict pathological proliferation and activation. Circ. Res. 2014, 115:625-635.
66. Chen W.C., et al. Human myocardial pericytes: multipotent mesodermal precursors exhibiting cardiac specificity. Stem Cells 2015, 33:557-573.
67. Iwayama T., et al. PDGFRα signaling drives adipose tissue fibrosis by targeting progenitor cell plasticity. Genes Dev. 2015, 29:1106-1119.
68. Diaz-Flores L., et al. Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche. Histol. Histopathol. 2009, 24:909-969.
69. van Amerongen M.J., et al. Bone marrow-derived myofibroblasts contribute functionally to scar formation after myocardial infarction. J. Pathol. 2008, 214:377-386.
70. Leone A.M., et al. Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. Eur. Heart J. 2005, 26:1196-1204.
71. Möllmann H., et al. Bone marrow-derived cells contribute to infarct remodelling. Cardiovasc. Res. 2006, 71:661-671.
72. Visconti R.P., et al. An in vivo analysis of hematopoietic stem cell potential: hematopoietic origin of cardiac valve interstitial cells. Circ. Res. 2006, 98:690-696.
73. Hajdu Z., et al. Recruitment of bone marrow-derived valve interstitial cells is a normal homeostatic process. J. Mol. Cell. Cardiol. 2011, 51:955-965.
74. Haudek S.B., et al. Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:18284-18289.
75. Keeley E.C., et al. The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of fibrotic disorders. Thromb. Haemost. 2009, 101:613-618.
76. Herzog E.L., Bucala R. Fibrocytes in health and disease. Exp. Hematol. 2010, 38:548-556.
77. Pilling D., et al. Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. PLoS ONE 2009, 4:e7475.
78. Yang J., et al. Transgenic tools for analysis of the haematopoietic system: knock-in CD45 reporter and deletor mice. J. Immunol. Methods 2008, 337:81-87.
79. Morimoto H., et al. Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice prevents cardiac dysfunction and remodeling after myocardial infarction. Circ. Res. 2006, 99:891-899.
80. Dewald O., et al. CCL2/monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ. Res. 2005, 96:881-889.
81. Dewald O., et al. Development of murine ischemic cardiomyopathy is associated with a transient inflammatory reaction and depends on reactive oxygen species. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:2700-2705.
82. Bujak M., et al. Induction of the CXC chemokine interferon-γ-inducible protein 10 regulates the reparative response following myocardial infarction. Circ. Res. 2009, 105:973-983.
83. Frangogiannis N.G., et al. Induction and suppression of interferon-inducible protein 10 in reperfused myocardial infarcts may regulate angiogenesis. FASEB J. 2001, 15:1428-1430.
84. Zhang G., et al. Myofibroblasts and the progression of experimental glomerulonephritis. Exp. Nephrol. 1995, 3:308-318.
85. Li Y., et al. Critical roles for the Fas/Fas ligand system in postinfarction ventricular remodeling and heart failure. Circ. Res. 2004, 95:627-636.
86. Kamo T., et al. Cardiac nonmyocytes in the hub of cardiac hypertrophy. Circ. Res. 2015, 117:89-98.
87. Takeda N., et al. Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J. Clin. Invest. 2010, 120:254-265.
88. Bang C., et al. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J. Clin. Invest. 2014, 124:2136-2146.
89. Soares A.R., et al. Gap junctional protein Cx43 is involved in the communication between extracellular vesicles and mammalian cells. Sci. Rep. 2015, 5:13243.
90. Yue L., et al. Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. Cardiovasc. Res. 2011, 89:744-753.
91. Abramochkin D., et al. Ion channels in cardiac fibroblasts: link to mechanically gated channels and their regulation. Mechanically Gated Channels and their Regulation 2012, 215-244. Springer Netherlands. A. Kamkin, I. Lozinsky (Eds.).
92. Li G.R., et al. Characterization of multiple ion channels in cultured human cardiac fibroblasts. PLoS ONE 2009, 4:e7307.
93. Adapala R.K., et al. TRPV4 channels mediate cardiac fibroblast differentiation by integrating mechanical and soluble signals. J. Mol. Cell. Cardiol. 2013, 54:45-52.
94. Davis J., et al. A TRPC6-dependent pathway for myofibroblast transdifferentiation and wound healing in vivo. Dev. Cell 2012, 23:705-715.
95. Reed A., et al. Molecular candidates for cardiac stretch-activated ion channels. Global Cardiol. Sci. Pract. 2014, 2014:9-25.
96. Peyronnet R., et al. Cardiac mechano-gated ion channels and arrhythmias. Circ. Res. 2016, 118:311-329.
97. Rook M.B., et al. Single channel currents of homo- and heterologous gap junctions between cardiac fibroblasts and myocytes. Pflugers Arch. Eur. J. Physiol. 1989, 414:95-98.
98. Rook M.B., et al. Differences in gap junction channels between cardiac myocytes, fibroblasts, and heterologous pairs. Am. J. Physiol. 1992, 263:C959-C977.
99. Gaudesius G., et al. Coupling of cardiac electrical activity over extended distances by fibroblasts of cardiac origin. Circ. Res. 2003, 93:421-428.
100. Rohr S. Myofibroblasts in diseased hearts: new players in cardiac arrhythmias?. Heart Rhythm 2009, 6:848-856.
101. Kohl P. Heterogeneous cell coupling in the heart: an electrophysiological role for fibroblasts. Circ. Res. 2003, 93:381-383.
102. Kohl P., Camelliti P. Fibroblast-myocyte connections in the heart. Heart Rhythm 2012, 9:461-464.
103. Zhang Y., et al. Remodeling of cardiac fibroblasts following myocardial infarction results in increased gap junction intercellular communication. Cardiovasc. Pathol. 2010, 19:e233-e240.
104. Vasquez C., et al. Enhanced fibroblast-myocyte interactions in response to cardiac injury. Circ. Res. 2010, 107:1011-1020.
105. Camelliti P., et al. Fibroblast network in rabbit sinoatrial node: structural and functional identification of homogeneous and heterogeneous cell coupling. Circ. Res. 2004, 94:828-835.
106. Camelliti P., et al. Structural and functional coupling of cardiac myocytes and fibroblasts. Adv. Cardiol. 2006, 42:132-149.
107. Rhett J.M., et al. The perinexus: sign-post on the path to a new model of cardiac conduction?. Trends Cardiovasc. Med. 2013, 23:222-228.
108. Veeraraghavan R., et al. Intercellular electrical communication in the heart: a new, active role for the intercalated disk. Cell Commun. Adhes. 2014, 21:161-167.
109. Rustom A., et al. Nanotubular highways for intercellular organelle transport. Science 2004, 303:1007-1010.
110. Chinnery H.R., et al. Cutting edge: membrane nanotubes in vivo: a feature of MHC class II+ cells in the mouse cornea. J. Immunol. 2008, 180:5779-5783.
111. Davis D.M., Sowinski S. Membrane nanotubes: dynamic long-distance connections between animal cells. Nat. Rev. Mol. Cell Biol. 2008, 9:431-436.
112. Marzo L., et al. Multifaceted roles of tunneling nanotubes in intercellular communication. Front. Physiol. 2012, 3:72.
113. He K., et al. Long-distance intercellular connectivity between cardiomyocytes and cardiofibroblasts mediated by membrane nanotubes. Cardiovasc. Res. 2011, 92:39-47.
114. Driesen R.B., et al. Partial cell fusion: a newly recognized type of communication between dedifferentiating cardiomyocytes and fibroblasts. Cardiovasc. Res. 2005, 68:37-46.
115. Watkins S.C., Salter R.D. Functional connectivity between immune cells mediated by tunneling nanotubules. Immunity 2005, 23:309-318.
116. Wang X., et al. Animal cells connected by nanotubes can be electrically coupled through interposed gap-junction channels. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:17194-17199.
117. Murakami M., Simons M. Fibroblast growth factor regulation of neovascularization. Curr. Opin. Hematol. 2008, 15:215-220.
118. Abbate A., et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am. J. Cardiol. 2010, 105:1371-1377.
119. Blankesteijn W.M., et al. A homologue of Drosophila tissue polarity gene frizzled is expressed in migrating myofibroblasts in the infarcted rat heart. Nat. Med. 1997, 3:541-544.
120. Bujak M., Frangogiannis N.G. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc. Res. 2007, 74:184-195.
121. Frangogiannis N.G. Chemokines in ischemia and reperfusion. Thromb. Haemost. 2007, 97:738-747.
122. Haudek S.B., et al. Monocytic fibroblast precursors mediate fibrosis in angiotensin-II-induced cardiac hypertrophy. J. Mol. Cell. Cardiol. 2010, 49:499-507.
123. Takemura G., et al. Role of apoptosis in the disappearance of infiltrated and proliferated interstitial cells after myocardial infarction. Circ. Res. 1998, 82:1130-1138.
124. Ghosh A.K., et al. Molecular basis of cardiac endothelial-to-mesenchymal transition (EndMT): differential expression of microRNAs during EndMT. Cell. Signal. 2012, 24:1031-1036.
125. Nagpal V., et al. MiR-125b is critical for fibroblast-to-myofibroblast transition and cardiac fibrosis. Circulation 2015, Published online November 19, 2015. 10.1161/CIRCULATIONAHA.115.018174.
126. van Rooij E., et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:13027-13032.
127. Roy S., et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc. Res. 2009, 82:21-29.
128. Thum T., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456:980-984.
129. Wang Y.S., et al. Role of miR-145 in cardiac myofibroblast differentiation. J. Mol. Cell. Cardiol. 2014, 66:94-105.
130. Duisters R.F., et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ. Res. 2009, 104:170-178.
131. Norris R.A., et al. Periostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissues. J. Cell. Biochem. 2007, 101:695-711.
132. Shimazaki M., et al. Periostin is essential for cardiac healing after acute myocardial infarction. J. Exp. Med. 2008, 205:295-303.
133. Oka T., et al. Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling. Circ. Res. 2007, 101:313-321.
134. Ladage D., et al. Stimulating myocardial regeneration with periostin peptide in large mammals improves function post-myocardial infarction but increases myocardial fibrosis. PLoS ONE 2013, 8:e59656.
135. Tourkina E., et al. Opposing effects of protein kinase Calpha and protein kinase Cepsilon on collagen expression by human lung fibroblasts are mediated via MEK/ERK and caveolin-1 signaling. J. Biol. Chem. 2005, 280:13879-13887.
136. Razani B., et al. Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD signaling through an interaction with the TGF-beta type I receptor. J. Biol. Chem. 2001, 276:6727-6738.
137. Lee R., et al. Caveolin-1 regulates chemokine receptor 5-mediated contribution of bone marrow-derived cells to dermal fibrosis. Front. Pharmacol. 2014, 5:140.
138. Del Galdo F., et al. Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum. 2008, 58:2854-2865.
139. Lee R., et al. Bleomycin delivery by osmotic minipump: similarity to human scleroderma interstitial lung disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 2014, 306:L736-L748.
140. Reese C., et al. Caveolin-1 deficiency may predispose African Americans to systemic sclerosis-related interstitial lung disease. Arthritis Rheumatol. 2014, 66:1909-1919.
141. Tourkina E., et al. Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide. Fibrogenesis Tissue Repair 2011, 4:15.
142. Cohen A.W., et al. Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts. Am. J. Physiol. Cell Physiol. 2003, 284:C457-C474.
143. Shivshankar P., et al. Caveolin-1 deletion exacerbates cardiac interstitial fibrosis by promoting M2 macrophage activation in mice after myocardial infarction. J. Mol. Cell. Cardiol. 2014, 76:84-93.
144. Miyasato S.K., et al. Caveolin-1 modulates TGF-β1 signaling in cardiac remodeling. Matrix Biol. 2011, 30:318-329.
145. Tourkina E., et al. Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008, 294:L843-L861.
146. Bucci M., et al. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat. Med. 2000, 6:1362-1367.
147. Holmes J.W., et al. Functional implications of myocardial scar structure. Am. J. Physiol. 1997, 272:H2123-H2130.
148. Zimmerman S.D., et al. Structural and mechanical factors influencing infarct scar collagen organization. Am. J. Physiol. Heart Circ. Physiol. 2000, 278:H194-H200.
149. Smith-Mungo L.I., Kagan H.M. Lysyl oxidase: properties, regulation and multiple functions in biology. Matrix Biol. 1998, 16:387-398.
150. Gonzalez-Santamaria J., et al. Matrix cross-linking lysyl oxidases are induced in response to myocardial infarction and promote cardiac dysfunction. Cardiovasc. Res. 2016, 109:67-78.
151. Lopez B., et al. Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. Am. J. Physiol. Heart Circ. Physiol. 2010, 299:H1-H9.
152. Fomovsky G.M., et al. Model-based design of mechanical therapies for myocardial infarction. J. Cardiovasc. Transl. Res. 2011, 4:82-91.
153. Schuster E.H., Bulkley B.H. Expansion of transmural myocardial infarction: a pathophysiologic factor in cardiac rupture. Circulation 1979, 60:1532-1538.
154. Nguyen T.P., et al. Arrhythmogenic consequences of myofibroblast-myocyte coupling. Cardiovasc. Res. 2012, 93:242-251.
155. Rohr S. Arrhythmogenic implications of fibroblast-myocyte interactions. Circ. Arrhythmia Electrophysiol. 2012, 5:442-452.
156. de Jong S., et al. Fibrosis and cardiac arrhythmias. J. Cardiovasc. Pharmacol. 2011, 57:630-638.
157. Vasquez C., Morley G.E. The origin and arrhythmogenic potential of fibroblasts in cardiac disease. J. Cardiovasc. Transl. Res. 2012, 5:760-767.
158. McDowell, Kathleen S., et al. Susceptibility to arrhythmia in the Infarcted heart depends on myofibroblast density. Biophys. J. 2011, 101:1307-1315.
159. Kohl P., et al. Mechanosensitive fibroblasts in the sino-atrial node region of rat heart: interaction with cardiomyocytes and possible role. Exp. Physiol. 1994, 79:943-956.
160. Xie Y., et al. Effects of fibroblast-myocyte coupling on cardiac conduction and vulnerability to reentry: a computational study. Heart Rhythm 2009, 6:1641-1649.
161. Hou L., et al. Genetically engineered excitable cardiac myofibroblasts coupled to cardiomyocytes rescue normal propagation and reduce arrhythmia complexity in heterocellular monolayers. PLoS ONE 2013, 8:e55400.
162. Yankelson L., et al. Cell therapy for modification of the myocardial electrophysiological substrate. Circulation 2008, 117:720-731.
163. Eloff B.C., et al. Pharmacological modulation of cardiac gap junctions to enhance cardiac conduction: evidence supporting a novel target for antiarrhythmic therapy. Circulation 2003, 108:3157-3163.
164. O'Quinn M.P., et al. A peptide mimetic of the connexin43 carboxyl-terminus reduces gap junction remodeling and induced arrhythmia following ventricular injury. Circ. Res. 2011, 108:704-715.
165. Fernandes S., et al. Cardiac cell therapy: overexpression of connexin43 in skeletal myoblasts and prevention of ventricular arrhythmias. J. Cell. Mol. Med. 2009, 13:3703-3712.
166. Roell W., et al. Engraftment of connexin 43-expressing cells prevents post-infarct arrhythmia. Nature 2007, 450:819-824.
167. Walker N.L., et al. Mapping of epicardial activation in a rabbit model of chronic myocardial infarction. J. Cardiovasc. Electrophysiol. 2007, 18:862-868.
168. Saba S., et al. Dual-dye optical mapping after myocardial infarction: does the site of ventricular stimulation alter the properties of electrical propagation?. J. Cardiovasc. Electrophysiol. 2008, 19:197-202.
169. Ripplinger C.M., et al. Panoramic imaging reveals basic mechanisms of induction and termination of ventricular tachycardia in rabbit heart with chronic infarction: implications for low-voltage cardioversion. Heart Rhythm 2009, 6:87-97.
170. Kohl P., et al. Electrical coupling of fibroblasts and myocytes: relevance for cardiac propagation. J. Electrocardiol. 2005, 38:45-50.
171. Quinn T.A., et al. Cell-specific expression of voltage-sensitive protein confirms cardiac myocyte to non-myocyte electrotonic coupling in healed murine infarct border tissue. Circulation 2014, 130:A11749.